About TransMedics Group, Inc. 
TransMedics Group, Inc.
Pharmaceuticals & Biotechnology
Transmedics group, Inc. is a commercial-stage medical technology company. It is focused on developing organ transplant therapy for end-stage organ failure patients across multiple disease states. The Company has designed and developed organ care system (OCS) a portable organ perfusion, optimization and monitoring system that utilizes customized technology to replicate near-physiologic conditions for donor organs outside of the human body. It has developed three OCS products, one for each of lung, heart and liver transplantations. Its OCS clinical programs include OCS Lung INSPIRE Trial, OCS Lung Expand Trial, OCs Heart EXPAND and PROCEED II Trials. Its organ care system (OCS) technology platform to perfuse donor organs with warm, oxygenated, nutrient-enriched blood, while maintaining the organs in a living, functioning state; the lung is breathing, the heart is beating and the liver is producing bile. It is also focused on developing additional OCS products for kidney transplantation.
Shareholding Snapshot
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 103 Schemes (71.76%)
Foreign Institutions
Held by 161 Foreign Institutions (31.59%)
Strategic Entities with highest holding
Highest Public shareholder
Management
Designation
Mr. James Tobin
Independent Chairman of the Board
Dr. Waleed Hassanein
President, Chief Executive Officer, Director
Ms. Merilee Raines
Director
Mr. Edward Basile
Independent Director
Mr. Thomas Gunderson
Independent Director
Mr. Edwin Kania
Independent Director
Dr. David Weill
Independent Director
Revenue and Profits:
Net Sales:
157 Million
(Quarterly Results - Jun 2025)
Net Profit:
35 Million
Pharmaceuticals & Biotechnology
USD 3,599 Million (Small Cap)
96.00
NA
0.00%
0.36
22.53%
11.31






